Registration - Amendment
GLENMARK PHARMACEUTICALS USA for GLENMARK PHARMACEUTICALS USA
Client
Income
—
Expenses
—
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
FDA User Fees, Tax Reform, Pharmaceutical Pricing
| Lobbyist | Covered position, as disclosed |
|---|---|
| GRANT ERDEL New | Legislative Correspondent - Senator Bond Administrative Assistant - Representative Jo Ann Emerson Senior Policy Advisor - Representative Charles Bass |
Health Issues HCR
FDA User Fees, Tax Reform, Pharmaceutical Pricing
| Lobbyist | Covered position, as disclosed |
|---|---|
| GRANT ERDEL New | Legislative Correspondent - Senator Bond Administrative Assistant - Representative Jo Ann Emerson Senior Policy Advisor - Representative Charles Bass |
Copyright/Patent/Trademark CPT
FDA User Fees, Tax Reform, Pharmaceutical Pricing
| Lobbyist | Covered position, as disclosed |
|---|---|
| GRANT ERDEL New | Legislative Correspondent - Senator Bond Administrative Assistant - Representative Jo Ann Emerson Senior Policy Advisor - Representative Charles Bass |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| GLENMARK PHARMACEUTICALS | India | India | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.